Pharmacodynamic Models for the Cardiovascular Effects of Moxonidine in Patients with Congestive Heart Failure

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2001 Feb 13

PMID 11167663

Citations 11

Authors

L Brynne

J L MCNAY

H G Schaefer

K Swedberg

C G Wiltse

M O Karlsson

Affiliations

Soon will be listed here.

Abstract

Aims: To assess the pharmacodynamics of moxonidine in patients with functional NYHA Class II-III congestive heart failure (CHF).

Methods: A parallel population pharmacokinetic/pharmacodynamic (PK/PD) analysis was performed to assess the effect of moxonidine (0.1, 0.2, 0.3 mg twice daily) and placebo treatment on plasma noradrenaline (NA) levels, standing systolic blood pressure (SBP), and heart rate (HR) over 12 weeks in 97 patients with CHF using a parallel group design with dose escalation. A sequential analysis was also developed, where the relative changes in NA concentration were related to both SBP and HR.

Results: In the parallel PD analysis, an effect delay was shown for all three end points (NA, SBP, and HR). An inhibitory Emax model was used to characterize the concentration-effect relationships. For SBP and HR, the EC50 value increased over time. For NA, there was a positive baseline drift over the 12 weeks; this was interpreted as disease progression. Moxonidine delayed this increase by 9.8 weeks. For SBP, there was a circadian pattern at baseline. In the sequential PD analysis, the relationship between the drug response (NA) and SBP or HR was best described by an inhibitory Emax model. No effect delays between the response and effects were found.

Conclusions: Effects of moxonidine on NA, SBP, and HR could be quantified by an effect compartment model in the presence of disease progression and circadian variations. Disease progression, as judged by increasing NA levels with time, was delayed by moxonidine. A direct relationship was found between NA and SBP/HR.

Citing Articles

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.

Centanni M, Thijs A, Desar I, Karlsson M, Friberg L Clin Transl Sci. 2022; 16(1):73-84.

PMID: 36152309 PMC: 9841306. DOI: 10.1111/cts.13423.

Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Gonzalez-Sales M, Nekka F, Tanguay M, Tremblay P, Li J Br J Clin Pharmacol. 2016; 83(6):1240-1251.

PMID: 28035697 PMC: 6396849. DOI: 10.1111/bcp.13225.

Differential analysis of transient increases of serum cTnI in response to handling in rats.

Mikaelian I, Dunn M, Mould D, Hirkaler G, Geng W, Coluccio D Pharmacol Res Perspect. 2014; 1(2):e00011.

PMID: 25505566 PMC: 4186429. DOI: 10.1002/prp2.11.

Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7.

Johansson A, Ueckert S, Plan E, Hooker A, Karlsson M J Pharmacokinet Pharmacodyn. 2014; 41(3):223-38.

PMID: 24801864 DOI: 10.1007/s10928-014-9359-z.

Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models.

Xu X, Wang H, Vermeulen A J Pharmacokinet Pharmacodyn. 2011; 38(3):353-67.

PMID: 21451962 DOI: 10.1007/s10928-011-9197-1.

References

Mandema J, Verotta D, Sheiner L . Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992; 20(5):511-28. DOI: 10.1007/BF01061469. View

Hempel G, Karlsson M, De Alwis D, Toublanc N, McNay J, Schaefer H . Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther. 1999; 64(6):622-35. DOI: 10.1016/S0009-9236(98)90053-4. View

Dutta S, Matsumoto Y, Ebling W . Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?. J Pharm Sci. 1996; 85(2):232-9. DOI: 10.1021/js950067y. View

Francis G, Cohn J, Johnson G, Rector T, Goldman S, Simon A . Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(6 Suppl):VI40-8. View

Holford N, Peace K . Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci U S A. 1992; 89(23):11471-5. PMC: 50573. DOI: 10.1073/pnas.89.23.11471. View

Dayneka N, Garg V, Jusko W . Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993; 21(4):457-78. PMC: 4207304. DOI: 10.1007/BF01061691. View

Sheiner L, Stanski D, Vozeh S, Miller R, Ham J . Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979; 25(3):358-71. DOI: 10.1002/cpt1979253358. View

Elliott H . Moxonidine: pharmacology, clinical pharmacology and clinical profile. Blood Press Suppl. 1999; 3:23-7. DOI: 10.1080/080370598438447-1. View

Cohn J, Archibald D, Ziesche S, Franciosa J, Harston W, Tristani F . Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1986; 314(24):1547-52. DOI: 10.1056/NEJM198606123142404. View

10.

Karlsson M, Sheiner L . The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993; 21(6):735-50. DOI: 10.1007/BF01113502. View

11.

Karlsson M, Jonsson E, Wiltse C, Wade J . Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998; 26(2):207-46. DOI: 10.1023/a:1020561807903. View

12.

Morris S, Reid J . Moxonidine: a review. J Hum Hypertens. 1997; 11(10):629-35. DOI: 10.1038/sj.jhh.1000518. View

13.

Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L . Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990; 82(5):1730-6. DOI: 10.1161/01.cir.82.5.1730. View

14.

Dickstein K, Manhenke C, Aarsland T, Kopp U, McNay J, Wiltse C . Acute hemodynamic and neurohumoral effects of moxonidine in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1999; 83(12):1638-44. DOI: 10.1016/s0002-9149(99)00170-8. View

15.

Yusuf S, Pitt B, Davis C, Hood W, Cohn J . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325(5):293-302. DOI: 10.1056/NEJM199108013250501. View

16.

. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316(23):1429-35. DOI: 10.1056/NEJM198706043162301. View

17.

Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55. DOI: 10.1056/NEJM199605233342101. View

18.

Pitt B, Zannad F, Remme W, Cody R, CASTAIGNE A, Perez A . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709-17. DOI: 10.1056/NEJM199909023411001. View

19.

Cohn J, Levine T, Olivari M, Garberg V, Lura D, Francis G . Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311(13):819-23. DOI: 10.1056/NEJM198409273111303. View

20.

Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View